BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
11,839
20,653
25,186
26,353
Cost of Revenue
1,600
471
1,702
2,699
Gross Profit
10,239
20,182
23,484
23,654
Operating Expenses
Research Development
103,725
84,888
66,962
61,008
Selling General and Administrative
31,122
29,514
13,933
11,253
Total Operating Expenses
134,847
114,402
80,895
72,261
Operating Income or Loss
-124,608
-94,220
-57,411
-48,607
Interest Expense
11,219
9,176
8,565
6,487
Total Other Income/Expenses Net
-111
-108
-821
-843
Income Before Tax
-133,707
-101,252
-65,782
-55,144
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-133,707
-101,252
-65,782
-55,144
Net Income
-133,707
-101,252
-65,782
-55,144
Net Income available to common shareholders
-133,707
-101,252
-65,782
-55,144
Reported EPS
Basic
-
-0.98
-0.78
-0.75
Diluted
-
-0.98
-0.78
-0.75
Weighted average shares outstanding
Basic
-
103,185
84,451
73,699
Diluted
-
103,185
84,451
73,699
EBITDA
-
-92,076
-57,217
-48,657